{
  "guideline": {
    "id": "PA166161219",
    "name": "Annotation of FDA Label for aripiprazole lauroxil and CYP2D6",
    "source": "FDA",
    "version": 27,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166161219",
    "relatedChemicals": [
      {
        "id": "PA166161216",
        "name": "aripiprazole lauroxil",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166312302",
      "name": "Recommendation Annotation PA166312302",
      "population": "ARISTADA INITIO Label",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166161216",
          "name": "aripiprazole lauroxil",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216561,
        "html": "<p>&quot;ARISTADA INITIO [aripiprazole lauroxil] is only available at a single strength as a single-dose pre-filled syringe, so dosage adjustments are not possible. Therefore, avoid use in patients who are known CYP2D6 poor metabolizers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166312323",
      "name": "Recommendation Annotation PA166312323",
      "population": "ARISTADA Label",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166161216",
          "name": "aripiprazole lauroxil",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216582,
        "html": "<p>The label states &quot;Dosage adjustment is recommended in known CYP2D6 poor metabolizers due to high aripiprazole concentrations.&quot; Table 4 of the label contains information for <em>a concomitant medicine that is a strong CYP3A4 inhibitor</em>: &quot;For patients known to be poor metabolizers of CYP2D6: Reduce dose to 441 mg from 662 mg, 882 mg, or 1064 mg. No dosage adjustment is necessary in patients taking 441 mg ARISTADA, if tolerated.&quot; See label for more information</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product ARISTADA (aripiprazole lauroxil), NDA207533, Alkermes, Inc.",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207533"
    },
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product ARISTADA INITIO (aripiprazole lauroxil), NDA209830, Alkermes, Inc.",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209830"
    }
  ],
  "version": "2024-02-29-20-19"
}